Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)
Open Access
- 10 February 2022
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 12 (2) , 1-8
Abstract
Measuring response among patients with multiple myeloma is essential for the care of patients. Deeper responses are associated with better progression free survival (PFS) and overall survival (OS). To test the hypothesis that Mass-Fix, a mass spectrometry-based means to detect monoclonal proteins, is superior to existing methodologies to predict for survival outcomes, samples from the STAMINA trial (NCT01109004), a trial comparing three transplant approaches, were employed. Samples from 575 patients from as many as three time points (post-induction [post-I; pre-maintenance [pre-M]; 1 year post enrollment [1YR]) were tested when available. Four response parameters were assessed: Mass-Fix, serum immunofixation, complete response, and measurable residual disease (MRD) by next generation flow cytometry. Of the four response measures, only MRD and Mass-Fix predicted for PFS and OS at multiple testing points on multivariate analyses. Although MRD drove Mass-Fix from the model for PFS at post-I and pre-M, 1YR Mass-Fix was independent of 1YR MRD. For OS, the only prognostic pre-I measure was Mass-Fix, and the only 1YR measures that were prognostic on multivariate analysis were 1YR MRD and 1YR Mass-Fix. SIFE and CR were not. Mass-Fix is a powerful means to track response.Keywords
This publication has 20 references indexed in Scilit:
- MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteinsClinica Chimica Acta, 2019
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 TrialJournal of Clinical Oncology, 2019
- A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interferenceBlood, 2018
- High sensitivity blood-based M-protein detection in sCR patients with multiple myelomaBlood Cancer Journal, 2017
- The utility of MASS‐FIX to detect and monitor monoclonal proteins in the clinicAmerican Journal of Hematology, 2017
- Comprehensive Assessment of M-Proteins Using Nanobody Enrichment Coupled to MALDI-TOF Mass SpectrometryClinical Chemistry, 2016
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myelomaThe Lancet Oncology, 2016
- Reagents and Cell Staining for Immunophenotyping by Flow Cytometry2014
- Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple MyelomaJournal of Clinical Oncology, 2011
- The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.Proceedings of the National Academy of Sciences, 1996